eliquis

CEOs of Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) defended the high prices of their drugs as they were grilled by the Senate Health Committee, led by Senator Bernie Sanders who submitted a report blasting the extravagant cost of three drugs. "Merck...

Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices for a month’s supply of these drugs were high then, and in 2024 their manufacturers have raised them higher still. According to data by 46brooklyn...

President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical companies such as Pfizer Inc. (NYSE: PFE) because drugs associated with the companies...

Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...

Jefferies said in a note Monday that upside asymmetry for Bristol-Myers Squibb Co (NYSE: BMY) is exhausted at current levels, with shares having already discounted M&A spec and biopharma flows. This, according to the firm, leaves significant downside risk if current study CM-227 fails. CM-...

Bristol-Myers Squibb Co (NYSE: BMY) reported strong 1Q results, while raising its guidance for 2016. 1Q Beat Goldman Sachs’ Jami Rubin mentioned that the company adjusted EPS for 1Q came in at $0.74, beating both the estimate and the consensus. Revenues at $4.39 billion also significantly...